Positive results from 5-7 years' follow-up of the first Episealer® Knee patients in a Swedish multicentre clinical trial
Episurf Medical (Nasdaq: EPIS B) today announces that the company has been informed about positive results in a clinical study with follow-up at 5-7 years of the 10 first patients to receive an Episealer® Knee implant. The principle investigator, MD PhD A. Stålman at Capio Artro Clinic in Stockholm, will now compile the results from this study for submission to a scientific journal. The study is a multicentre study performed at three Swedish clinics. It is a continuation of a previous study (“No implant migration and good subjective outcome of a novel customized femoral resurfacing